Featured Research

from universities, journals, and other organizations

Drug Does Not Appear To Reduce Risk Of Heart Attack Or Death Following CABG Surgery

Date:
April 1, 2008
Source:
JAMA and Archives Journals
Summary:
Use of MC-1 (a naturally occurring metabolite of vitamin B6) before and for 30 days after coronary artery bypass graft surgery did not reduce the risk of heart attack or cardiovascular death, according to a new study.

Use of MC-1 (a naturally occurring metabolite of vitamin B6) before and for 30 days after coronary artery bypass graft surgery did not reduce the risk of heart attack or cardiovascular death, according to a new study.

"Coronary artery bypass graft (CABG) surgery is one of the most important therapeutic options for relieving angina and improving survival and quality of life in patients with multivessel coronary artery disease. It is the most commonly performed cardiac surgical procedure in the world, and in 2005, more than 250,000 CABG procedures were performed in the United States," the authors write. Serious complications can include heart attack, recurrent angina, kidney insufficiency, stroke, and death. Phase 2 trial data suggest that MC-1 may reduce death or heart attack in high-risk patients undergoing CABG surgery.

John H. Alexander, M.D., M.H.S., of Duke University Medical Center, Duke Clinical Research Institute, Durham, N.C., and colleagues with MEND-CABG II, a phase 3, multicenter, randomized trial, assessed the cardioprotective effect of MC-1 administered before and continued for 30 days after CABG surgery, compared with placebo, in 3,023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass.

The researchers found that the primary efficacy outcome, cardiovascular death or nonfatal heart attack at 30 days, occurred in 140 of 1,510 patients (9.3 percent) in the MC-1 group and 133 of 1,486 patients (9.0 percent) in the placebo group. All-cause death was higher among patients assigned to MC-1 than placebo at 4 days (1.0 percent vs. 0.3 percent) but was similar at 30 days (1.9 percent vs. 1.5 percent). There was no beneficial effect of MC-1 seen in any prespecified subgroup or on other outcomes.

There was no difference in the incidence of postoperative stroke, atrial fibrillation, or kidney function between the two groups. Patients assigned to receive MC-1 and placebo had similar intensive care unit and hospital lengths of stay.

"MEND-CABG II demonstrates that among intermediate- to high-risk patients undergoing CABG surgery, MC-1, 250 mg/d, given immediately before and for 30 days following surgery did not reduce cardiovascular death or nonfatal [heart attack]. Myocardial injury remains a significant problem following CABG surgery. Effective therapies to reduce perioperative morbidity and mortality are needed but remain elusive," the authors conclude.

Journal reference: JAMA. 2008;299[15]:doi:10.1001/jama.299.15.joc80027


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Drug Does Not Appear To Reduce Risk Of Heart Attack Or Death Following CABG Surgery." ScienceDaily. ScienceDaily, 1 April 2008. <www.sciencedaily.com/releases/2008/04/080401161639.htm>.
JAMA and Archives Journals. (2008, April 1). Drug Does Not Appear To Reduce Risk Of Heart Attack Or Death Following CABG Surgery. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/04/080401161639.htm
JAMA and Archives Journals. "Drug Does Not Appear To Reduce Risk Of Heart Attack Or Death Following CABG Surgery." ScienceDaily. www.sciencedaily.com/releases/2008/04/080401161639.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins